BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) announced today it has received approval from the Japanese Ministry of Health, Labor and Welfare (Shonin) to market the CyberKnife® Robotic Radiosurgery System for the treatment of trigeminal neuralgia (TN) in Japan.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide.

Crescita Therapeutics Inc. announced today that the Toronto Stock Exchange (the “ TSX ”) has approved the Company’s renewal of its existing normal course issuer bid (“ NCIB ”) for a portion of its common shares (“ Common Shares ”) as appropriate opportunities arise from time to time.

Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals.

CoImmune, Inc., today announced that results from a Phase 1/2 clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform.

Humacyte, Inc. today announced that results from a case study of a patient who received the human acellular vessel (HAV) as a replacement for an infected synthetic iliofemoral bypass graft.

Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific body of the European Medicines Agency (EMA) accepted its request for an accelerated assessment of the etranacogene dezaparvovec Marketing Authorisation Application (MAA).

Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11197869, covering the intravenous delivery of istaroxime for the treatment of acute heart failure.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR.

Outlook Therapeutics, Inc. today announced that Francesco Bandello, MD, FEBO, Professor and Chairman of the Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele, Milan, will present pivotal safety and efficacy data at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia, on Saturday, December 18, 2021.